|
|
|
| home > white papers > Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models - DrugDev |
|
|
 WHITE PAPERS |
|
DrugDev
|
|
Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models
|
|
For the last 20 years, pharmaceutical companies have turned to a variety
of clinical outsourcing solutions to reduce costs and improve
timelines, enabling them to focus on their core value of research and
development. In today’s tightly competitive market, companies are
constantly striving for ways to further cut costs and reduce study
startup cycle times, while maintaining quality.
One of the key
cost factors in global R&D spending, estimated at around $102
billion per Kalorama market research, is the cost of conducting clinical
trials. CRO’s, which account for about 30% of the total R&D
spending, have risen to the challenge of the clinical, technical and
administrative management of these trials. But some pharmaceutical
companies question how much control to relinquish to vendor partners,
especially in the legal arena, due to potential ramifications.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development
MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >> |
|
 |
White Papers |
 |
|
Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody
RSSL
Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >> |
|
 |
Industry Events |
 |
The Universe of Pre-filled Syringes and Injection Devices
22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel
PDA’s Universe of Pre-filled Syringes and Injection
Devices has become the must-attend meeting for everyone
working in the field, and is now the world’s largest conference on this subject
More info >> |
|
|
|
